Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Sep 29. doi: 10.1056/NEJMoa1908681. [Epub ahead of print]

PMID:
31566307
2.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators.

N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.

PMID:
31112379
3.

[Treatment of carbon monoxide poisoning in Germany : A retrospective single center analysis].

Eichhorn L, Kieback M, Michaelis D, Kemmerer M, Jüttner B, Tetzlaff K.

Anaesthesist. 2019 Apr;68(4):208-217. doi: 10.1007/s00101-019-0544-8. Epub 2019 Feb 21. German.

PMID:
30789991
4.

Effects of Breath-Hold Deep Diving on the Pulmonary System.

Schipke JD, Lemaitre F, Cleveland S, Tetzlaff K.

Respiration. 2019;97(5):476-483. doi: 10.1159/000495757. Epub 2019 Feb 15. Review.

PMID:
30783070
5.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

6.

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.

Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465818755091. doi: 10.1177/1753465818755091.

7.

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.

Calverley PM, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 29;12:3391-3405. doi: 10.2147/COPD.S145814. eCollection 2017.

8.

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L.

NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1.

9.

Carbon monoxide poisoning from waterpipe smoking: a retrospective cohort study.

Eichhorn L, Michaelis D, Kemmerer M, Jüttner B, Tetzlaff K.

Clin Toxicol (Phila). 2018 Apr;56(4):264-272. doi: 10.1080/15563650.2017.1375115. Epub 2017 Sep 14.

PMID:
28906147
10.

Short- and long-term effects of diving on pulmonary function.

Tetzlaff K, Thomas PS.

Eur Respir Rev. 2017 Mar 29;26(143). pii: 160097. doi: 10.1183/16000617.0097-2016. Print 2017 Mar 31.

11.

Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Mezzanotte W, Disse B, Finnigan H, Asijee G, Hallmann C, Watz H.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-1221. doi: 10.1164/rccm.201612-2525LE. No abstract available.

PMID:
28306321
12.

Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease.

Ichinose M, Kato M, Takizawa A, Sakamoto W, Grönke L, Tetzlaff K, Fukuchi Y.

Respir Investig. 2017 Mar;55(2):121-129. doi: 10.1016/j.resinv.2016.09.004. Epub 2016 Dec 22.

PMID:
28274527
13.

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.

Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.

Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14.

14.

Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.

Rodriguez-Roisin R, Tetzlaff K, Watz H, Wouters EF, Disse B, Finnigan H, Magnussen H, Calverley PM.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 22;11:1973-81. doi: 10.2147/COPD.S106142. eCollection 2016.

15.

The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium.

Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, Tal-Singer R, Kawata A, Merrill D, Rennard S; COPD Biomarker Qualification Consortium.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1483-1493.

16.

Last Word on Viewpoint: Why predominantly neurological decompression sickness in breath-hold divers?

Schipke JD, Tetzlaff K.

J Appl Physiol (1985). 2016 Jun 15;120(12):1483. doi: 10.1152/japplphysiol.00285.2016. No abstract available.

17.

Risk of Neurological Insult in Competitive Deep Breath-Hold Diving.

Tetzlaff K, Schöppenthau H, Schipke JD.

Int J Sports Physiol Perform. 2017 Feb;12(2):268-271. doi: 10.1123/ijspp.2016-0042. Epub 2016 Aug 24.

PMID:
27248853
18.

Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM.

Lancet Respir Med. 2016 May;4(5):390-8. doi: 10.1016/S2213-2600(16)00100-4. Epub 2016 Apr 7.

PMID:
27066739
19.

Evaluation of thermal regimes for transported ambassador ectotherms: One size does not fit all.

Tetzlaff SJ, Tetzlaff KE, Connors RJ 2nd.

Zoo Biol. 2016 Jul;35(4):339-45. doi: 10.1002/zoo.21283. Epub 2016 Mar 23.

PMID:
27007783
20.

Why predominantly neurological decompression sickness in breath-hold divers?

Schipke JD, Tetzlaff K.

J Appl Physiol (1985). 2016 Jun 15;120(12):1474-7. doi: 10.1152/japplphysiol.00840.2015. Epub 2016 Jan 21. No abstract available.

21.

Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD.

Magnussen H, Tetzlaff K, Bateman ED, Watz H, Kirsten AM, Wouters EF, Disse B, Finnigan H, Rodriguez-Roisin R, Calverley PM.

Eur Respir J. 2016 Feb;47(2):651-4. doi: 10.1183/13993003.01644-2015. Epub 2015 Nov 19. No abstract available.

22.

[Hyperbaric therapy and diving medicine - hyperbaric therapy part 1: evidence-based emergency care].

Jüttner B, Tetzlaff K.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2015 Oct;50(10):618-25; quiz 626. doi: 10.1055/s-0041-102628. Epub 2015 Nov 2. Review. German.

PMID:
26523604
23.

[Hyperbaric therapy and diving medicine - hyperbaric therapy part 2: adjuvant therapy].

Tetzlaff K, Jüttner B.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2015 Oct;50(10):628-35; quiz 636. doi: 10.1055/s-0041-107111. Epub 2015 Oct 28. Review. German.

PMID:
26510108
24.

Antioxidants may Attenuate Plasma Erythropoietin Decline after Hyperbaric Oxygen Diving.

Mutzbauer TS, Schneider M, Neubauer B, Weiss M, Tetzlaff K.

Int J Sports Med. 2015 Nov;36(13):1035-40. doi: 10.1055/s-0035-1555782. Epub 2015 Aug 10.

PMID:
26258821
25.

Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E.

Eur Respir J. 2015 Jun;45(6):1763. doi: 10.1183/09031936.50136014. No abstract available.

26.

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.

Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.

Pulm Pharmacol Ther. 2015 Jun;32:53-9. doi: 10.1016/j.pupt.2015.04.002. Epub 2015 May 6.

27.

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.

Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, Finnigan HA, Bateman ED, Rand Sutherland E.

Pulm Pharmacol Ther. 2015 Jun;32:37-44. doi: 10.1016/j.pupt.2015.03.003. Epub 2015 Apr 8.

28.

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.

McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT.

COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18.

29.

Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.

Mannino DM, Tal-Singer R, Lomas DA, Vestbo J, Graham Barr R, Tetzlaff K, Lowings M, Rennard SI, Snyder J, Goldman M, Martin UJ, Merrill D, Martin AL, Simeone JC, Fahrbach K, Murphy B, Leidy N, Miller B.

Chronic Obstr Pulm Dis. 2015;2(1):23-34.

30.

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E.

Eur Respir J. 2015 Apr;45(4):969-79. doi: 10.1183/09031936.00136014. Epub 2015 Jan 8. Erratum in: Eur Respir J. 2015 Jun;45(6):1763.

31.

Inhaled glucocorticoids and COPD exacerbations.

Magnussen H, Tetzlaff K, Calverley PM.

N Engl J Med. 2015 Jan 1;372(1):93-4. doi: 10.1056/NEJMc1413308. No abstract available.

PMID:
25551535
32.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators.

N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.

33.

[Emergency checklist drowning].

Tetzlaff K, Muth CM.

MMW Fortschr Med. 2014 Jun 12;156(11):49. German. No abstract available.

PMID:
25022102
34.

Lung function after cold-water dives with a standard scuba regulator or full-face-mask during wintertime.

Uhlig F, Muth CM, Tetzlaff K, Koch A, Leberle R, Georgieff M, Winkler BE.

Diving Hyperb Med. 2014 Jun;44(2):70-3.

PMID:
24986723
35.

Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.

Magnussen H, Watz H, Kirsten A, Decramer M, Dahl R, Calverley PM, Towse L, Finnigan H, Tetzlaff K, Disse B.

Respir Med. 2014 Apr;108(4):593-9. doi: 10.1016/j.rmed.2014.01.002. Epub 2014 Jan 15.

36.

Modified ventilatory response characteristics to exercise in breath-hold divers.

Roecker K, Metzger J, Scholz T, Tetzlaff K, Sorichter S, Walterspacher S.

Int J Sports Physiol Perform. 2014 Sep;9(5):757-65. doi: 10.1123/ijspp.2013-0308. Epub 2013 Nov 14.

PMID:
24231513
37.

Different reactions of human nasal and Eustachian tube mucosa after hyperbaric oxygen exposure: a pilot study.

Mutzbauer TS, Neubauer B, Tetzlaff K.

Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1249-53. doi: 10.1007/s00405-012-2115-3. Epub 2012 Jul 25.

PMID:
22829159
38.

Effects of FLIRT on bubble growth in man.

Winkler BE, Koch A, Schoeppenthau H, Ludwig T, Tetzlaff K, Hartig F, Kaehler W, Koehler A, Kanstinger A, Ciscato W, Muth CM.

Int J Sports Med. 2012 Nov;33(11):903-8. doi: 10.1055/s-0032-1306328. Epub 2012 Jun 15.

PMID:
22706940
39.

Effect of simulated diving trips on pulmonary artery pressure in healthy men.

Hansel J, Burgstahler C, Medler S, Axmann D, Niess AM, Tetzlaff K.

Clin Res Cardiol. 2012 Dec;101(12):947-53. doi: 10.1007/s00392-012-0482-9. Epub 2012 Jun 14.

PMID:
22695534
40.

[Need for differentiating decompression illness].

Tetzlaff K, Muth CM, Klingmann C.

Dtsch Med Wochenschr. 2012 May;137(18):963; author reply 964. doi: 10.1055/s-0032-1304934. Epub 2012 Apr 24. German. No abstract available.

PMID:
22531944
41.

Should children dive with self-contained underwater breathing apparatus (SCUBA)?

Winkler BE, Muth CM, Tetzlaff K.

Acta Paediatr. 2012 May;101(5):472-8. doi: 10.1111/j.1651-2227.2011.02589.x. Epub 2012 Jan 23. Review.

PMID:
22212048
42.

SCUBA-dive-related changes in heart rate in children.

Winkler BE, Tetzlaff K, Muth CM, Paulat K, Hebestreit H.

Pediatr Exerc Sci. 2011 Aug;23(3):388-98.

PMID:
21881159
43.

Effect of simulated dives on diastolic function in healthy men.

Hansel J, Tetzlaff K, Axmann D, Niess AM, Burgstahler C.

Eur J Appl Physiol. 2012 Jan;112(1):193-9. doi: 10.1007/s00421-011-1953-9. Epub 2011 Apr 23.

PMID:
21516341
44.

Breath-hold diving: respiratory function on the longer term.

Walterspacher S, Scholz T, Tetzlaff K, Sorichter S.

Med Sci Sports Exerc. 2011 Jul;43(7):1214-9. doi: 10.1249/MSS.0b013e31820a4e0c.

PMID:
21200343
45.

In vivo inhibition of epidermal growth factor receptor autophosphorylation prevents receptor internalization.

Wolff M, Tetzlaff K, Nivens MC, Schneider FJ, Jung B, Hohlfeld J, Heilker R.

Exp Cell Res. 2011 Jan 1;317(1):42-50. doi: 10.1016/j.yexcr.2010.09.009. Epub 2010 Sep 18.

PMID:
20858487
46.

Pulmonary function in children after open water SCUBA dives.

Winkler BE, Tetzlaff K, Muth CM, Hebestreit H.

Int J Sports Med. 2010 Oct;31(10):724-30. doi: 10.1055/s-0030-1262803. Epub 2010 Jul 30.

PMID:
20677123
47.

Glossopharyngeal insufflation and pulmonary hemodynamics in elite breath hold divers.

Eichinger M, Walterspacher S, Scholz T, Tetzlaff R, Puderbach M, Tetzlaff K, Kopp-Schneider A, Ley S, Choe K, Kauczor HU, Sorichter S.

Med Sci Sports Exerc. 2010 Sep;42(9):1688-95. doi: 10.1249/MSS.0b013e3181d85dc3.

PMID:
20195178
48.

Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.

Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, Criner GJ, Kim V, Prasse A, Nivens MC, Tetzlaff K, Heilker R, Fahy JV.

Am J Respir Crit Care Med. 2010 Mar 1;181(5):438-45. doi: 10.1164/rccm.200909-1415OC. Epub 2009 Dec 10.

PMID:
20007923
49.

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.

Monz BU, Sachs P, McDonald J, Crawford B, Nivens MC, Tetzlaff K.

Respir Med. 2010 Apr;104(4):534-41. doi: 10.1016/j.rmed.2009.10.026. Epub 2009 Nov 14.

50.

Hypoxia and cardiac arrhythmias in breath-hold divers during voluntary immersed breath-holds.

Hansel J, Solleder I, Gfroerer W, Muth CM, Paulat K, Simon P, Heitkamp HC, Niess A, Tetzlaff K.

Eur J Appl Physiol. 2009 Mar;105(5):673-8. doi: 10.1007/s00421-008-0945-x. Epub 2008 Nov 26.

PMID:
19034490

Supplemental Content

Loading ...
Support Center